Treatment to Regress to Normoglycemia in Women With a Recent History of GDM
Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the efficacy of semaglutide 1mg (Ozempic®) to aid
recently postpartum women with dysglycemia and a history of GDM to regress to normoglycemia;
thereby filling a gap in efficacious pharmacologic intervention options for clinicians to
support postpartum diabetes recovery and reduce future risk of T2DM in young women.